| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| W W Fleischhacke. New developments in the pharmacotherapy of schizophrenia. Journal of neural transmission. Supplementum. issue 64. 2003-08-06. PMID:12830932. |
while the concept of partial d1-agonism has already led to the successful launch of a new antipsychotic, aripiprazole, the other attempts to improve therapeutic response in schizophrenia patients have so far provided equivocal results. |
2003-08-06 |
2023-08-12 |
Not clear |
| Toya M Bowles, Gary M Levi. Aripiprazole: a new atypical antipsychotic drug. The Annals of pharmacotherapy. vol 37. issue 5. 2003-06-23. PMID:12708948. |
to review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of aripiprazole for the treatment of schizophrenia. |
2003-06-23 |
2023-08-12 |
Not clear |
| D M Taylo. Aripiprazole: a review of its pharmacology and clinical use. International journal of clinical practice. vol 57. issue 1. 2003-05-19. PMID:12587943. |
once-daily aripiprazole 15-30 mg is as effective as haloperidol 10 mg/day and risperidone 6 mg/day in short-term treatment of schizophrenia and more effective than haloperidol 7-10 mg/day in maintenance of response in chronic schizophrenia. |
2003-05-19 |
2023-08-12 |
Not clear |
| Jane K McGavin, Karen L Go. Aripiprazole. CNS drugs. vol 16. issue 11. 2003-04-04. PMID:12383035. |
in patients with acute relapse of schizophrenia or schizoaffective disorder, aripiprazole 15 to 30 mg/day was at least as effective as haloperidol 10 mg/day and had similar efficacy to risperidone 6 mg/day in well designed, 4-week, placebo-controlled trials. |
2003-04-04 |
2023-08-12 |
Not clear |
| Jane K McGavin, Karen L Go. Aripiprazole. CNS drugs. vol 16. issue 11. 2003-04-04. PMID:12383035. |
aripiprazole was superior to placebo in a 26-week trial in patients with stable, chronic schizophrenia. |
2003-04-04 |
2023-08-12 |
Not clear |
| Aripiprazole (Abilify) for schizophrenia. The Medical letter on drugs and therapeutics. vol 45. issue 1150. 2003-03-20. PMID:12592215. |
aripiprazole (abilify) for schizophrenia. |
2003-03-20 |
2023-08-12 |
Not clear |
| Vural Ozdemir, Jeanne Fourie, Fatih Ozdene. Aripiprazole (Otsuka Pharmaceutical Co). Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054061. |
otsuka pharmaceuticals in collaboration with bristol-myers squibb is developing aripiprazole, a dual dopamine autoreceptor agonist and postsynaptic d2 receptor antagonist, for the potential treatment of psychoses including schizophrenia [281327], [340364]. |
2002-12-17 |
2023-08-12 |
Not clear |
| Vural Ozdemir, Jeanne Fourie, Fatih Ozdene. Aripiprazole (Otsuka Pharmaceutical Co). Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054061. |
moreover, the mechanism of action of aripiprazole differentiates it from both typical and atypical antipsychotics and hence, may provide important leads for pharmacotherapy of schizophrenia and other psychotic disorders. |
2002-12-17 |
2023-08-12 |
Not clear |
| John M Kane, William H Carson, Anutosh R Saha, Robert D McQuade, Gary G Ingenito, Dan L Zimbroff, Mirza W Al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry. vol 63. issue 9. 2002-10-11. PMID:12363115. |
efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. |
2002-10-11 |
2023-08-12 |
Not clear |
| John M Kane, William H Carson, Anutosh R Saha, Robert D McQuade, Gary G Ingenito, Dan L Zimbroff, Mirza W Al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry. vol 63. issue 9. 2002-10-11. PMID:12363115. |
aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile. |
2002-10-11 |
2023-08-12 |
Not clear |
| Fuji Yokoi, Gerhard Gründer, Kathleen Biziere, Massoud Stephane, Ahmet S Dogan, Robert F Dannals, Hayden Ravert, Ajit Suri, Steven Bramer, Dean F Won. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 27. issue 2. 2002-08-07. PMID:12093598. |
this underlines aripiprazole's unique mechanism of action as a partial dopamine receptor agonist, which might become a novel principle in the treatment of schizophrenia. |
2002-08-07 |
2023-08-12 |
human |
| J M Cañive, J D Lewine, J C Edgar, J T Davis, G A Miller, F Torres, V B Tuaso. Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. Psychopharmacology bulletin. vol 34. issue 1. 1998-05-21. PMID:9580382. |
spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. |
1998-05-21 |
2023-08-12 |
human |
| J M Cañive, J D Lewine, J C Edgar, J T Davis, G A Miller, F Torres, V B Tuaso. Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. Psychopharmacology bulletin. vol 34. issue 1. 1998-05-21. PMID:9580382. |
the schizophrenia subjects underwent a second meg recording after 8 weeks of open-label treatment with aripiprazole. |
1998-05-21 |
2023-08-12 |
human |